In view of the above discussion, the investigators believe that although MHC could serve to be a potent chemotherapeutic for the management of triple negative breast cancer, before reaching to such a conclusion, further studies are warranted. The gene discussed is HLA-C; the disease is triple-negative breast carcinoma.